LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ)
$0.1927 0.0052 (2.7733%)
Analysed LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) News Sources
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
17-03-2026
yahoo.com
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
17-02-2026
yahoo.com
BC-Most Active Stocks
09-02-2026
yahoo.com
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
30-10-2025
yahoo.com
BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism
05-08-2025
coindesk.com
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
25-07-2025
yahoo.com
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
24-07-2025
yahoo.com
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
22-07-2025
yahoo.com
What is the current price of LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ)?
The current price of LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) is $0.1927.
LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) absolute price change since previous trading day?
The absolute price change of LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) since the previous trading day is $0.0052.
LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) percentage price change since previous trading day?
The percentage price change of LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) since the previous trading day is 2.7733%.
What is the most recent average sentiment score for LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ)?
The most recent average sentiment score for LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) is 58 out of 100.
What is the most recent average sentiment for LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ)?
The most recent sentiment for LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ) is .
SEC-8K** Filing Available For LIMINATUS PHARMA INC-CL A (LIMN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.